Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

NCT06526195 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

Interventions

  • DEVICE CardioMEMS HF System
  • DEVICE HeartMate 3 Left Ventricular Assist System
  • OTHER Guideline Medical Directed Therapy

Study Locations (20)

Georgia

  • Piedmont Heart Institute — Atlanta
  • Piedmont Augusta Hospital — Augusta
  • WellStar Kennestone Hospital — Marietta

California

  • Sutter Medical Center — Sacramento
  • University of California at San Francisco — San Francisco

Florida

  • Shands at the University of Florida — Gainesville
  • Cleveland Clinic Florida — Weston

Kentucky

  • University of Kentucky — Lexington
  • Norton Hospital — Louisville

Michigan

  • Henry Ford Hospital — Detroit
  • Spectrum Health Butterworth Hospital — Grand Rapids

Arizona

  • Banner-University Medical Center Phoenix — Phoenix

Arkansas

  • Baptist Health Medical Center — Little Rock

District of Columbia

  • Washington Hospital Center — Washington D.C.

Trial Details

FieldValue
Enrollment Target 850 participants
Start Date 2024-12-13
Est. Completion 2032-09
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06526195

The ClinicalTrials.gov registry entry for NCT06526195 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions — of which CardioMEMS HF System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06526195 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Georgia, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06526195 about?

NCT06526195 is a clinical study titled "Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure". The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

What is the current status of trial NCT06526195?

This trial is currently recruiting. It is a NA study. The enrollment target is 850 participants. The study started on 2024-12-13. Estimated completion is 2032-09.

What conditions does trial NCT06526195 study?

This clinical trial studies the following conditions: Heart Failure, Cardiovascular Diseases, Heart Diseases, Pulmonary Hypertension. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06526195?

The interventions under investigation include: CardioMEMS HF System (DEVICE), HeartMate 3 Left Ventricular Assist System (DEVICE), Guideline Medical Directed Therapy (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06526195?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06526195 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial